XOLAIR® (omalizumab) prescribing information (external link)
This page includes promotional meetings and events organised and funded by Novartis Pharmaceuticals UK Ltd. Novartis products may be mentioned on this page and/or subsequent event pages.
Respiratory and inflammation
XOLAIR® (omalizumab)
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
